home

4D Pharma Acquires Instituto Biomar

EVENTSgenengnews2016-04-13 09:37 Read   84

Drug developer 4D Pharma said today it has acquired the production assets of Instituto Biomar, a contract research organization specializing in microbial fermentation, for up to €6 million ($6.8 million).

Post-Shkreli KaloBios pledges transparent pricing

EVENTSpmlive2016-04-13 09:07 Read   86

 A company drawn into the price gouging scandal has promised to adhere to an affordable and transparent pricing policy for its drugs in future.

Celgene and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-directed Product Candidates

EVENTSbusinesswire2016-04-12 13:05 Read   105

“The long-term collaboration with Celgene is an important component of our plan to develop our engineered T cell platform rapidly and effectively for the benefit of patients around the world, and we are encouraged by the progress we are making together.”

Tobira Therapeutics and Dong-A ST Enter Into License Agreements for Evogliptin and Cenicriviroc

EVENTSstockhouse2016-04-12 12:58 Read   97

Tobira gains rights to second asset for NASH in North America, Europe & Australia First combination study with cenicriviroc to begin late 2016 Conference Call Scheduled for today at 8:30 a.m. ET

Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics

EVENTSregeneron2016-04-12 11:27 Read   86

Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. In addition to the discovery, development and commercialization of new therapies, the companies will focus on technology development of the CRISPR/Cas platform.

Please don’t hate us anymore; KaloBios’ new CEO takes a drug pricing oath

EVENTSfiercebiotech2016-04-12 11:15 Read   65

Biotech companies like KaloBios rarely like to publicly discuss their drug pricing strategies. It’s not a popular topic and they typically don’t have any products on the market that need to be priced anyway. But then, most biotech companies don’t have to distance themselves from one-time CEOs like Martin Shkreli.

Viamet Revisits IPO Plans, This Time With More Dataea

EVENTSxconomy2016-04-12 11:08 Read   73

Viamet Pharmaceuticals is taking another swing at the public markets, filing plans for an initial public offering intended to finance the work needed to bring its lead antifungal drug to the brink of late-stage clinical studies in two types of infections.

Venter's HLI valued at $1.2B in Series B round

EVENTSfiercebiotech2016-04-11 11:21 Read   86

J. Craig Venter's Human Longevity, Inc. has refueled in the race to build an industry-leading repository of genomes and associated data. The refueling took the form of a $220 million Series B round, which reportedly valued the company at upward of $1.2 billion and attracted the support of long-time HLI backers Celgene ($CELG) and Illumina ($ILMN).

Shire says Baxalta merger on track despite US tax clampdown

EVENTSPmlive2016-04-08 17:17 Read   110

Shire has said it is confident its $32bn deal to buy Baxalta will go ahead as planned, despite the abandonment of Pfizer's merger with Allergan.

Amgen’s Response to Technology Assessments for Kyprolis® (Carfilzomib) in Multiple Myeloma

EVENTSAmgen2016-04-07 14:23 Read   127

At the same time as the pace of innovation in the fight against cancer has increased, so has the use of “technology assessments” to understand the economic value of innovation.

Allergan, Pfizer Cancel $160B Merger, Citing U.S. Treasury Actions

EVENTSXconomy2016-04-07 13:52 Read   94

Xconomy New York — The speculation turned out to be true: Pfizer and Allergan announced today that they are canceling a proposed $160 billion merger, in large part due to steps the U.S. Treasury Department is planning to prevent tax avoidance.

Picking winners still possible in Q1

EVENTSEP vantage2016-04-07 13:38 Read   106

Even in down markets there are wins to be had. Most mid and small-cap biopharma companies were in the red in the first quarter of 2016, but some groups were able to steer towards share price rises against the prevailing headwinds that left their bigger counterparts struggling to eke out any gains.